LIGAND PHARMACEUTICALS INC
For the period ended Sep 30, 2026. Filed Oct 30, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Oct 30, 2026
LGND$314.16+0.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Comprehensive Income (Loss)
| Three months ended · Nine months ended | ||||
|---|---|---|---|---|
| September 30, | September 30, | |||
| 2026 | 2025 | 2026 | 2025 | |
| Net (loss) income | $(28,485) | $117,273 | $6,678 | $79,669 |
| Unrealized (loss) gain on available-for-sale securities, net of tax | (821) | 78 | (1,575) | 7 |
| Foreign currency translation adjustment, net of tax | (216) | 750 | (3,441) | 15,257 |
| Comprehensive (loss) income | $(29,522) | $118,101 | $1,662 | $94,933 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.